NADAC acquisition cost data for RISPERDAL CONSTA 50 MG VIAL. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 50458030811 | $1,072.26 | 2022-01-19 | Rx |
| 50458030811 | $1,072.26 | 2022-01-19 | Rx |
| 50458030811 | $1,072.26 | 2022-01-19 | Rx |
| 50458030811 | $1,072.26 | 2022-01-19 | Rx |
| 50458030811 | $1,072.26 | 2022-01-19 | Rx |
| 50458030811 | $1,072.26 | 2022-01-19 | Rx |
| 50458030811 | $1,072.26 | 2022-01-19 | Rx |
| 50458030811 | $1,072.26 | 2022-01-19 | Rx |
| 50458030811 | $1,072.26 | 2022-01-19 | Rx |
| 50458030811 | $1,072.26 | 2022-01-19 | Rx |
Generic: Risperidone | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $11.5M | 10,082 | 1,350 | $17.74 |
| 2020 | $11.3M | 9,442 | 1,199 | $17.87 |
| 2021 | $9.2M | 8,707 | 1,098 | $15.39 |
| 2022 | $4.4M | 8,094 | 1,038 | $7.76 |
| 2023 | $4.2M | 7,428 | 957 | $7.82 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $611.1K | 1,199 | 123 |
| California | $377.6K | 507 | 84 |
| Texas | $320.4K | 511 | 81 |
| New Jersey | $248.9K | 387 | 53 |
| Florida | $247.8K | 417 | 60 |
| Pennsylvania | $204.8K | 456 | 61 |
| North Carolina | $187.7K | 340 | 40 |
| Ohio | $176.1K | 413 | 44 |
| Illinois | $159.4K | 265 | 38 |
| Michigan | $158.7K | 324 | 37 |
| Connecticut | $99.2K | 166 | 28 |
| Massachusetts | $98.1K | 187 | 25 |
| Georgia | $88.5K | 111 | 19 |
| Wisconsin | $79.5K | 182 | 20 |
| Indiana | $78.7K | 144 | 17 |
| South Carolina | $78.7K | 118 | 20 |
| Tennessee | $70.9K | 90 | 17 |
| Oregon | $57.8K | 119 | 14 |
| Minnesota | $56.2K | 100 | 14 |
| Arizona | $51.2K | 71 | 12 |
| Kentucky | $48.6K | 86 | 13 |
| Colorado | $43.9K | 89 | 14 |
| Puerto Rico | $41.5K | 94 | 11 |
| Maryland | $38.7K | 63 | 11 |
| Virginia | $38.6K | 104 | 12 |
| Washington | $38.4K | 65 | N/A |
| Nebraska | $36.4K | 70 | N/A |
| Oklahoma | $33.3K | 55 | N/A |
| Missouri | $31.1K | 52 | N/A |
| Louisiana | $29.5K | 43 | N/A |
| New Hampshire | $29.0K | 51 | N/A |
| District of Columbia | $27.7K | 34 | N/A |
| North Dakota | $26.3K | 24 | N/A |
| Hawaii | $24.2K | 14 | N/A |
| Maine | $23.1K | 42 | N/A |
| Alabama | $22.6K | 40 | N/A |
| Kansas | $22.1K | 38 | N/A |
| Utah | $19.8K | 34 | N/A |
| Idaho | $18.7K | 47 | N/A |
| Delaware | $18.4K | 37 | N/A |
| Vermont | $16.4K | 31 | N/A |
| Nevada | $15.3K | 25 | N/A |
| Mississippi | $14.4K | 23 | N/A |
| West Virginia | $14.2K | 35 | N/A |
| Iowa | $12.3K | 16 | N/A |
| Arkansas | $9.2K | 35 | N/A |
| New Mexico | $8.7K | 14 | N/A |
| Rhode Island | $8.4K | 17 | N/A |
| Montana | $4.9K | 26 | N/A |
| South Dakota | $3.5K | 16 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.